Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass and DUBLIN, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on December 2, the Company granted to four newly hired employees (i) non-statutory stock options to purchase an aggregate of 26,300 ordinary shares of the Company and (ii) restricted stock units with respect to an aggregate of 13,200 ordinary shares of the Company, pursuant to the Company's 2024 Inducement Stock Option and Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
馬薩諸塞州沃爾瑟姆和都柏林，2024年12月03日（全球新聞社） - Mural Oncology plc（納斯達克股票代碼：MURA）是一家處於臨床階段的免疫腫瘤學公司，開發新穎的，調查中的工程細胞因子治療，旨在解決多種癌症患者所面臨的未滿足需求領域。公司今天宣佈，於12月2日向四名新僱員授予（i）購買公司共計26,300股普通股的非統計股票期權和（ii）限制性股票單位，涉及公司共計13,200股普通股，根據公司的2024年誘因股票期權和激勵計劃，每項均作爲對新員工按照納斯達克上市規則5635(c)(4)進入公司僱傭的誘因材料。
The stock options have an exercise price of $4.18 per share, which is equal to the closing price per share of the Company's ordinary shares as reported by Nasdaq on December 2, 2024. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the grant date and 6.25% of the shares underlying the options vesting quarterly thereafter, subject to such employee's continued service with the Company through the applicable vesting dates. Each of the stock options is subject to the terms and conditions of a stock option award agreement covering the grant and the Company's 2024 Inducement Stock Option and Incentive Plan. The restricted stock units vest over four years, 25% per year on the anniversary of the grant date, subject to such employee's continued service with the Company through the applicable vesting dates. Each of the restricted stock units is subject to the terms and conditions of a restricted stock award agreement covering the grant and the Company's 2024 Inducement Stock Option and Incentive Plan.
這些股票期權的行使價格爲每股4.18美元，這與公司普通股在2024年12月2日納斯達克報告的收盤價格相等。期權的有效期爲十年，並在四年內分期兌現，其中25%的原始股份在授予日期的第一週年兌現，其後每季度兌現6.25%的期權股份，前提是該員工在相關兌現日期持續爲公司服務。每個股票期權都受限於股票期權授予協議的條款和條件，以及公司的2024年誘導股票期權和激勵計劃。限制性股票單位在四年內分期兌現，每年在授予日期的週年上兌現25%，前提是該員工在相關兌現日期持續爲公司服務。每個限制性股票單位均受限於適用於授予的限制性股票獎勵協議的條款和條件，以及公司的2024年誘導股票期權和激勵計劃。
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. By combining our expertise in cytokine biology and immune cell modulation and our protein engineering platform, we are developing medicines to deliver meaningful and clinical benefits to people living with cancer. Our mission is to broaden the potential and reach of cytokine-based immunotherapies to improve the lives of patients. Our lead candidate, nemvaleukin, is currently in potentially registrational trials in mucosal melanoma and platinum-resistant ovarian cancer. Mural Oncology has its registered office in Dublin, Ireland, and its primary facilities in Waltham, Mass. For more information, visit Mural Oncology's website at and follow us on LinkedIn and X.
關於Mural Oncology
Mural Oncology正利用其新型蛋白質工程平台開發基於細胞因子的免疫療法以治療癌症。通過結合我們在細胞因子生物學和免疫細胞調節方面的專長以及我們的蛋白質工程平台，我們正在開發藥物，以爲癌症患者提供有意義的臨床益處。我們的使命是擴大基於細胞因子的免疫療法的潛力和覆蓋範圍，以改善患者的生活。我們的主要候選藥物nemvaleukin目前正在進行粘膜黑色素瘤和鉑耐藥卵巢癌的潛在註冊試驗。Mural Oncology的註冊辦公室位於愛爾蘭都柏林，主要設施位於馬薩諸塞州沃爾瑟姆。欲了解更多信息，請訪問Mural Oncology的網站並關注我們的LinkedIn和X。
Contact
聯繫方式
Katie Sullivan
katie.sullivan@muraloncology.com
凱蒂·沙利文
katie.sullivan@muraloncology.com
譯文內容由第三人軟體翻譯。
